Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Tumor flare pain reaction during teclistamab step-up dosing with tocilizumab prophylaxis: An underrecognized toxicity in the outpatient setting

Gaspard Jadot, Richard LeBlanc, Rayan Kaedbey et al. Nov 03, 2025 pp. 5794-5794 10.1182/blood-2025-5794

Abstract Background: Teclistamab is a BCMA-directed bispecific antibody approved for the treatment of relapsed and refractory multiple myelo...

“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”

Henri Fero, Frenki Gjika, Ester Faccin et al. Nov 03, 2025 pp. 6872-6872 10.1182/blood-2025-6872

Abstract Background: Philadelphia chromosome–negative (Ph–) ALL is a genetically heterogeneous entity defined by recurrent cytogenetic and m...

Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma

Puja Aggarwal, Robert Bone, Blaise Nwotchouang et al. Nov 03, 2025 pp. 4572-4572 10.1182/blood-2025-4572

Abstract Introduction: Despite therapeutic advances in relapsed/refractory multiple myeloma (RRMM), optimal sequencing remains a clinical ch...

Real-world evidence from China: Clinical characteristics, treatment landscape and long-term outcomes in 566 autoimmune hemolytic anemia patients

Junan Zhang, Jiewen Qiu, Yizhou Zheng et al. Nov 03, 2025 pp. 2878-2878 10.1182/blood-2025-2878

Abstract Objective: Autoimmune hemolytic anemia (AIHA) is the most prevalent form of acquired hemolytic anemia, representing a heterogeneous...

Tracing the evolution of clonal T cell responses in LGL leukemia with single-cell whole genome sequencing

Aino Häkkinen, Sofia Forstén, Sofie Lundgren et al. Nov 03, 2025 pp. 3523-3523 10.1182/blood-2025-3523

Abstract Background T cell large granular lymphocytic leukemia (T-LGLL) is a rare hematological disease of clonally expanded mature cytotoxic...

Distinct morphological features of malignant cells in large B-cell lymphoma identified by soft-segmentation in imaging-based spatial proteomics

Junming Shi, Troy Noordenbos, Marieke IJsselsteijn et al. Nov 03, 2025 pp. 4342-4342 10.1182/blood-2025-4342

Abstract Background: Mature B-cell neoplasms display densely packed and morphologically heterogeneous cells, often complicating tissue-level...

The clinical utility of MALDI-TOF MS in multiple myeloma

Jialu Wu, Xia Ge, Zhiyao Zhang et al. Nov 03, 2025 pp. 2230-2230 10.1182/blood-2025-2230

Abstract Introduction: Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) can detect their mass-to-...

High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost

Maria Leon-Camarena, Leah Philips, Joseph Rimando et al. Nov 03, 2025 pp. 6394-6394 10.1182/blood-2025-6394

Abstract For myelofibrosis (MF) patient's undergoing hematopoietic stem cell transplant (HSCT) engraftment failure is a life-threatening cha...

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

Daniel Wiseman, Jak Laight, Rebecca Boucher et al. Nov 03, 2025 pp. 488-488 10.1182/blood-2025-488

Abstract Background Chronic myelomonocytic leukemia (CMML) and the rarer MDS/MPN overlap syndromes share biological features, poor prognosis...

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Nickolas Tsakmaklis, Alberto Guijosa, Andrés Ramírez et al. Nov 03, 2025 pp. 224-224 10.1182/blood-2025-224

Abstract Background: BTK-inhibitors and chemotherapy (CT) with rituximab are widely used frontline treatments in Waldenström Macroglobulinem...

Transgenic expression of enhanced AsCas12a in mice enables In Vivo multiplex genetic editing and development of diverse novel models of myeloid neoplasms

(Justin) Ching Ting Loke, Jared Brown, Marie McConkey et al. Nov 03, 2025 pp. 3227-3227 10.1182/blood-2025-3227

Abstract A central challenge for the development of engineered models of myeloid malignancies is the genetic complexity of human disease, as...

Patients with multiple sclerosis above age 60 have neurological responses to autologous hematopoietic stem cell transplants similar to younger individuals: A single center experience

Miguel Viveros Lugo, Lidia Alberto López, Michelle Lavoignet Cisneros et al. Nov 03, 2025 pp. 7615-7615 10.1182/blood-2025-7615

Abstract Background: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, characterized by inflammation, demyelin...

A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study)

Eduardo Edelman Saul, Jessie Xu, Casey Bermack et al. Nov 03, 2025 pp. 5434-5434 10.1182/blood-2025-5434

Abstract BackgroundFirst-line (1L) therapy for peripheral T-cell lymphoma (PTCL) is cyclophosphamide, doxorubicin, vincristine and prednison...

Use of red cell deformability measurements to assess the impact of pyruvate kinase activators on combined drug and transfusion therapies

Abhinav Pasupuleti, Akshay Patwardhan, Ashwin Patel et al. Nov 03, 2025 pp. 6136-6136 10.1182/blood-2025-6136

Abstract Background Sickle cell disease (SCD) is characterized by poorly deformable red blood cells (RBC) that worsen wi...

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

Patrizia Porazzi, Martina Pucillo, Anushka Anant Padmanabhan et al. Nov 03, 2025 pp. 2160-2160 10.1182/blood-2025-2160

Abstract Introduction: Although BCMA-targeted CAR-T therapies and CD3×BCMA bispecifics (e.g., teclistamab) have shown clinical promise, most...

Race-based disparities in hemorrhagic stroke mortality with underlying coagulopathies: A CDC-wonder analysis (1999–2020)

Khadija Mohib, Muhammad Asjad Saleem, Ubaid Ahmed et al. Nov 03, 2025 pp. 6639-6639 10.1182/blood-2025-6639

Abstract Background: Hemorrhagic stroke with coagulopathies carries a high risk of mortality and disability. Despite advances in care, dispa...

Novel CD117 T-cell engagers for targeted bone marrow HSPC depletion

Mukul Girotra, Evelyn Sauer, Ouliana Barneoud-Rousset et al. Nov 03, 2025 pp. 2305-2305 10.1182/blood-2025-2305

Abstract Bone marrow transplantation (BMT), aimed at replacing a defective hematopoietic system with a healthy one, offers curative potentia...

Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A nationwide analysis

Himil Mahadevia, Karnav Modi, Raj Shah et al. Nov 03, 2025 pp. 8012-8012 10.1182/blood-2025-8012

Abstract Introduction: CAR T-cell therapy is an important treatment option for patients with relapsed or refractory (R/R) DLBCL. Three CAR T...

Disease burden and treatment patterns in patients with previously treated primary immune thrombocytopenia (ITP): A retrospective study using administrative claims data in the United States

Joao Da Silva, Yu-Chen Yeh, Firas Dabbous et al. Nov 03, 2025 pp. 7990-7990 10.1182/blood-2025-7990

Abstract Introduction Primary immune thrombocytopenia (ITP) is a rare autoimmune bleeding disorder characterized by increased platelet destr...

The phosphorylation by aurkb regulates transcriptional functions of KLF1 during erythropoiesis

Rachael White, Raja Sundari Sundaram, Anita Dhara et al. Nov 03, 2025 pp. 1115-1115 10.1182/blood-2025-1115

Abstract Erythroid Krüppel-like factor (EKLF/KLF1) is a master transcriptional regulator of erythropoiesis, and when KLF1 is mutated, it lea...

Inferior vena cava agenesis presenting as iliofemoral deep vein thrombosis in a 49-year-old male

Eduardo Leon, Garrett Cherry, Karen Romero et al. Nov 03, 2025 pp. 6664-6664 10.1182/blood-2025-6664

Abstract Introduction Inferior vena cava (IVC) agenesis is a rare congenital anomaly, often asymptomatic until early adulthood, when it may...

A human IL-6–Expressing PDX model of multiple myeloma recapitulates clinical features and supports patient-derived tumor engraftment

Bonell Patiño-Escobar, Natasha Mariathasan, Jose Rivera et al. Nov 03, 2025 pp. 3943-3943 10.1182/blood-2025-3943

Abstract Background: Multiple myeloma (MM) is a malignancy of plasma cells characterized by bone destruction, anemia, and renal failure. Alth...

A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia

Samuel Yates, Elizabeth Terman, Lauren Miller et al. Nov 03, 2025 pp. 5153-5153 10.1182/blood-2025-5153

Abstract Introduction: A comprehensive geriatric assessment (CGA) is recommended in older adults (OAs, age>60 years) with acute myelo...

Burden of immune thrombocytopenia in hospitalized myeloid leukemia patients: Analysis from a national inpatient database

Tijin Mathew, Ahmed AL Sharie, Benjamin Easow et al. Nov 03, 2025 pp. 6917-6917 10.1182/blood-2025-6917

Abstract Background Chronic lymphocytic leukemia (CLL) and Acute lymphocytic leukemia are the most commonly known leukemias that cause immun...

Treatment initiation pattern, ramp-up measures and management of AML patients treated in real life in Italy with venetoclax+azacitidine - first interim analysis of the prospective vero study

Marta Ubezio, Caterina Alati, lorenzo celona et al. Nov 03, 2025 pp. 3383-3383 10.1182/blood-2025-3383

Abstract Introduction The VERO study (NCT06058741)aims to collect real-world data on effectiveness and safety of the com...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page